Molecular Imaging for Neuroendocrine Tumors: Somatostatin Receptor-Based Diagnostics

Systematic review of molecular imaging in neuroendocrine tumor diagnosis covers somatostatin receptor-based PET/CT and SPECT, guiding diagnostic and treatment selection decisions.

Alonzo, Laura et al.·EJNMMI reports·2025·Strong EvidenceMeta-Analysis
RPEP-09895Meta AnalysisStrong Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Meta-Analysis
Evidence
Strong Evidence
Sample
N=large
Participants
Patients with neuroendocrine tumors of unknown primary origin across reviewed imaging studies

What This Study Found

Systematic review of molecular imaging in neuroendocrine tumor diagnosis covers somatostatin receptor-based PET/CT and SPECT, guiding diagnostic and treatment selection decisions.

Key Numbers

Systematic review examining diagnostic accuracy of multiple molecular imaging modalities for CUP-NETs.

How They Did This

Methodology in publication.

Why This Research Matters

Relevant to peptide-based therapeutic applications.

The Bigger Picture

Contributes to peptide therapeutic evidence.

What This Study Doesn't Tell Us

Limitations in publication.

Questions This Raises

  • ?Long-term implications?
  • ?Comparison to evidence?
  • ?Next research?

Trust & Context

Key Stat:
Key finding Systematic review of molecular imaging in neuroendocrine tumor diagnosis covers somatostatin recepto
Evidence Grade:
Based on study design.
Study Age:
Published in 2025.
Original Title:
Molecular imaging in the diagnostic process of neuroendocrine tumors: a systematic review on unknown primary origin and suspected NETs.
Published In:
EJNMMI reports, 9(1), 38 (2025)
Database ID:
RPEP-09895

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Combines results from multiple studies to find an overall pattern.

What do these levels mean? →

Frequently Asked Questions

What does this mean?

Systematic review of molecular imaging in neuroendocrine tumor diagnosis covers somatostatin receptor-based PET/CT and SPECT, guiding diagnostic and treatment selection decisions.

How reliable?

Consult publication and provider.

Read More on RethinkPeptides

Cite This Study

RPEP-09895·https://rethinkpeptides.com/research/RPEP-09895

APA

Alonzo, Laura; Cannella, Roberto; Laudicella, Riccardo; Benfante, Viviana; Purpura, Pierpaolo; Micci, Giuseppe; Galia, Massimo; Brancatelli, Giuseppe; Midiri, Massimo; Alongi, Pierpaolo. (2025). Molecular imaging in the diagnostic process of neuroendocrine tumors: a systematic review on unknown primary origin and suspected NETs.. EJNMMI reports, 9(1), 38. https://doi.org/10.1186/s41824-025-00274-4

MLA

Alonzo, Laura, et al. "Molecular imaging in the diagnostic process of neuroendocrine tumors: a systematic review on unknown primary origin and suspected NETs.." EJNMMI reports, 2025. https://doi.org/10.1186/s41824-025-00274-4

RethinkPeptides

RethinkPeptides Research Database. "Molecular imaging in the diagnostic process of neuroendocrin..." RPEP-09895. Retrieved from https://rethinkpeptides.com/research/alonzo-2025-molecular-imaging-in-the

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.